The company also announced upcoming presentations at the American Society of Nephrology (ASN) Kidney Week 2025, November 6-9 in Houston, Texas highlighting data from more patients with longer duration ...
Sana Biotechnology, Inc. is a Strong Buy with promising cell therapies for diabetes & B-cell disorders. Click here to find ...
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for sonrotoclax, a ...
The FDA has granted breakthrough therapy designation (BTD) to the investigational B-cell lymphoma 2 (BCL2) inhibitor ...
JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy ...
Purpose of Study: The purpose of this study is to establish the safety and potential effectiveness of investigational FT819 in participants with moderate to severe systemic lupus erythematosus (SLE) ...
CAR T-cell therapy was first developed as a lymphoma treatment but has recently been applied to autoimmune diseases, primarily lupus, systemic sclerosis, and myositis. Up to this point, ulcerative ...
Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma In the POLARIX study (ClinicalTrials.gov identifier: NCT03274492), polatuzumab vedotin plus rituximab, ...
Background: B-cell activating factor (BAFF) is crucial for B-cell survival, proliferation, and immunoglobulin secretion. However, its role in hematopoietic malignancies, particularly concerning B-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback